Carregant...
Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
AIMS: Lenvatinib was recently approved for the treatment of radioiodine‐refractory differentiated thyroid cancer (RR‐DTC). Here, we characterized the pharmacokinetic (PK) profile of lenvatinib and identified intrinsic and extrinsic factors that explain interindividual PK variability in humans. METHO...
Guardat en:
| Publicat a: | Br J Clin Pharmacol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley and Sons Inc.
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4876185/ https://ncbi.nlm.nih.gov/pubmed/26879594 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12907 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|